Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2023.106970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Pengxing He und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Quinazolines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Targeting the epidermal growth factor receptor (EGFR) has been recognized as an effective strategy for treating non-small-cell lung cancer (NSCLC). Although several representative EGFR inhibitors have been approved for clinical use, it is highly desirable to develop highly potent and selective EGFR inhibitors with novel scaffolds because of the occurrence of acquired resistance after treatment. Here we first demonstrate that the 4-indolyl quinazoline derivatives could potently inhibit EGFR in vitro and in vivo, of which YS-67 effectively and selectively inhibits EGFR[WT] (IC50 = 5.2 nM), EGFR[d746-750] (IC50 = 9.6 nM) and EGFR[L858R] (IC50 = 1.9 nM). The TREEspot™ kinase interaction map further reveals the binding selectivity toward 468 kinases. YS-67 not only potently suppresses p-EGFR and p-AKT, but also effectively inhibits proliferation of A549 (IC50 = 4.1 μM), PC-9 (IC50 = 0.5 μM) and A431 cells (IC50 = 2.1 μM). YS-67 treatment also causes colony formation inhibition, arrests cell cycle progression at G0/G1 phases and induces apoptosis. More importantly, YS-67 is well tolerated in A431 xenograft model after oral administration, showing effective tumor growth suppression and low toxicity. Collectively, YS-67 represents an underexplored scaffold for developing new EGFR inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China…
- College of Chemistry, Zhengzhou University, Zhengzhou 450001, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Henan…
- Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Provincial Key Laboratory of Anticancer Drug Research, Henan Cancer Hospital, Zhengzhou 450008, China. Electr…
Zitieren
APA
He, P., Du, L., Dai, Q., Li, G., Yu, B., & Chang, L. (2024). Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.106970
Vancouver
He P, Du L, Dai Q, Li G, Yu B, Chang L. Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2023.106970
BibTeX
@article{He2024,
author = {He, Pengxing and Du, Linna and Dai, Qingqing and Li, Guobo and Yu, Bin and Chang, Linlin},
title = {Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2023.106970}
}
EUVIMED